In vitro neuraminidase inhibitory activity of four neuraminidase inhibitors against clinical isolates of the influenza virus circulating in the Japanese 2013-2014 season

被引:14
|
作者
Ikematsu, Hideyuki [1 ]
Kawai, Naoki [1 ]
Iwaki, Norio [1 ]
Kashiwagi, Seizabro [1 ]
机构
[1] Japan Phys Assoc, Tokyo, Japan
关键词
Influenza; 50% Inhibitory concentration; Oseltamivir; Zanamivir; Laninamivir; Peramivir; HYDRATE; PCR;
D O I
10.1016/j.jiac.2015.05.004
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
To assess the extent of viral resistance, we measured the 50% inhibitory concentration (IC50) of neuraminidase inhibitors (NAIs) for the influenza virus isolates in the 2013-2014 influenza season and compared the results to those of the 2010-2011 to 2012-2013 influenza seasons. Viral isolation was done with specimens obtained prior to treatment, and the type and subtype of influenza was determined by RT-PCR using type-and subtype-specific primers. The IC50 was determined by a neuraminidase inhibition assay using a fluorescent substrate. A total of 327 influenza viruses were isolated: 172 influenza A(H1N1) pdm09 (52.6%), 49 A(H3N2) (15.0%), and 106 B (32.4%). Numbers of Victoria and Yamagata lineage isolates were 36 and 70, respectively. Two A(H1N1) pdm09 isolates showed a high IC50 for oseltamivir (130 and 150 nM) exceeding by 100 times the geometric mean of the IC50 of oseltamivir for A(H1N1) pdm09 isolates (0.76 nM). No isolate showed a very high IC50 for A(H3N2) or B. The IC50 of the NAIs except for oseltamivir for A(H1N1) pdm09 were significantly higher than those of the 2010-2011 season (P < 0.05). The IC50 of all four NAIs for A(H3N2) were significantly lower than those of the 2012-2013 season (P < 0.001). The IC50 of the NAIs for B except for oseltamivir were significantly lower than those of the 2012-2013 season (P < 0.001). Although there are some isolates that show highly reduced sensitivity to oseltamivir among A(H1N1) pdm09 isolates, the currently epidemic influenza A(H1N1) pdm09, A(H3N2) and B viruses are susceptible to all four NAIs with no trend toward decreased sensitivity. (C) 2015, Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:634 / 638
页数:5
相关论文
共 31 条
  • [21] Structure-activity relationship of flavonoids as influenza virus neuraminidase inhibitors and their in vitro anti-viral activities
    Liu, Ai-Lin
    Wang, Hai-Di
    Lee, Simon MingYuen
    Wang, Yi-Tao
    Du, Guan-Hua
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY, 2008, 16 (15) : 7141 - 7147
  • [22] In vitro neuraminidase inhibitory effect and activity against influenza virus A H1N1 of herbal drugs used for common cold
    Biagi, M.
    Baini, G.
    Miraldi, E.
    Terrosi, C.
    Cusi, M. G.
    [J]. PLANTA MEDICA, 2019, 85 (18) : 1535 - 1536
  • [23] SUSCEPTIBILITY OF COMMERCIAL NEURAMINIDASE INHIBITORS AGAINST 2013 A/H7N9 INFLUENZA VIRUS: A DOCKING AND MOLECULAR DYNAMICS STUDY
    Yang, Zhiwei
    Wu, Fei
    Liu, Junxing
    Wang, Shuqiu
    Yuan, Xiaohui
    [J]. JOURNAL OF THEORETICAL & COMPUTATIONAL CHEMISTRY, 2013, 12 (07):
  • [24] Comparison of the activities of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates of influenza virus and neuraminidase inhibitor-resistant variants
    Gubareva, LV
    Webster, RG
    Hayden, FG
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (12) : 3403 - 3408
  • [25] Clinical effectiveness of four neuraminidase inhibitors (oseltamivir, zanamivir, laninamivir, and peramivir) for children with influenza A and B in the 2014-2015 to 2016-2017 influenza seasons in Japan
    Ishiguro, Nobuhisa
    Koseki, Naoko
    Kaiho, Miki
    Ariga, Tadashi
    Kikuta, Hideaki
    Oba, Koji
    Togashi, Takehiro
    Morita, Keisuke
    Inagawa, Akira
    Okamura, Akiko
    Yamazaki, Shigeru
    Shida, Satoru
    Konno, Mutsuko
    Kawamura, Nobuaki
    Ishizaka, Akihito
    Takada, Kimihiko
    Tsubakihara, Keiji
    Nagano, Naoko
    Shibata, Mutsuo
    Furuyama, Hideto
    Matsuzono, Yoshihiro
    Koike, Akemi
    Murashita, Mari
    Hatae, Yoshio
    Arioka, Hideki
    Yamanaka, Tatsuru
    Watanabe, Toru
    Tabata, Yuuichi
    Kumita, Yoshihiro
    Hazama, Kyosuke
    Akutsu, Yasushi
    Aoyagi, Hayato
    Tobise, Chie
    Azuma, Katsuki
    Yasoshima, Kohichi
    Sawada, Yoko
    Uetsuji, Kazuyuki
    Tsuchida, Akira
    Tsuchiyama, Akira
    Yasuda, Kazue
    Odagawa, Yasuhisa
    Yoshioka, Mikio
    [J]. JOURNAL OF INFECTION AND CHEMOTHERAPY, 2018, 24 (06) : 449 - 457
  • [26] In Vitro Anti-viral Activities and Structure-activity Relationship Studies of Flavones and Dihydroflavone Derivatives as Influenza Virus Potential Neuraminidase Inhibitors
    Sun Jia-Ying
    He Yun-Qing
    Du Hui-Rong
    Liu Chang-Lu
    Chen An-Yin
    Mei Hu
    [J]. CHINESE JOURNAL OF STRUCTURAL CHEMISTRY, 2015, 34 (11) : 1641 - 1651
  • [27] Clinical and virologic effects of four neuraminidase inhibitors in influenza A virus-infected children (aged 4-12 years): an open-label, randomized study in Japan
    Hirotsu, Nobuo
    Saisho, Yutaka
    Hasegawa, Takahiro
    Shishido, Takao
    [J]. EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2018, 16 (02) : 173 - 182
  • [28] In vitro activity of favipiravir and neuraminidase inhibitor combinations against oseltamivir-sensitive and oseltamivir-resistant pandemic influenza A (H1N1) virus
    E. Bart Tarbet
    Almut H. Vollmer
    Brett L. Hurst
    Dale L. Barnard
    Yousuke Furuta
    Donald F. Smee
    [J]. Archives of Virology, 2014, 159 : 1279 - 1291
  • [29] In vitro activity of favipiravir and neuraminidase inhibitor combinations against oseltamivir-sensitive and oseltamivir-resistant pandemic influenza A (H1N1) virus
    Tarbet, E. Bart
    Vollmer, Almut H.
    Hurst, Brett L.
    Barnard, Dale L.
    Furuta, Yousuke
    Smee, Donald F.
    [J]. ARCHIVES OF VIROLOGY, 2014, 159 (06) : 1279 - 1291
  • [30] Moderate influenza vaccine effectiveness against influenza A(H1N1)pdm09 virus and low effectiveness against A(H3N2) virus among older adults during 2013-2014 influenza season in Beijing, China
    Zhang, Li
    Pan, Yang
    Ma, Chunna
    Duan, Wei
    Sun, Ying
    Wu, Shuangsheng
    Zhang, Man
    Tian, Yi
    Zheng, Yang
    Yang, Peng
    Wang, Quanyi
    [J]. HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2018, 14 (06) : 1323 - 1330